IL163884A0 - Treatment of central nervous systemdamage - Google Patents

Treatment of central nervous systemdamage

Info

Publication number
IL163884A0
IL163884A0 IL16388403A IL16388403A IL163884A0 IL 163884 A0 IL163884 A0 IL 163884A0 IL 16388403 A IL16388403 A IL 16388403A IL 16388403 A IL16388403 A IL 16388403A IL 163884 A0 IL163884 A0 IL 163884A0
Authority
IL
Israel
Prior art keywords
systemdamage
treatment
central nervous
cns
mammal
Prior art date
Application number
IL16388403A
Other languages
English (en)
Original Assignee
King S College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King S College London filed Critical King S College London
Publication of IL163884A0 publication Critical patent/IL163884A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Purification Treatments By Anaerobic Or Anaerobic And Aerobic Bacteria Or Animals (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Carbon And Carbon Compounds (AREA)
IL16388403A 2002-03-04 2003-03-04 Treatment of central nervous systemdamage IL163884A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0205022.7A GB0205022D0 (en) 2002-03-04 2002-03-04 Materials and methods for the treatment of cns damage
PCT/GB2003/000901 WO2003074080A1 (en) 2002-03-04 2003-03-04 Treatment of central nervous system damage

Publications (1)

Publication Number Publication Date
IL163884A0 true IL163884A0 (en) 2005-12-18

Family

ID=9932221

Family Applications (3)

Application Number Title Priority Date Filing Date
IL16388403A IL163884A0 (en) 2002-03-04 2003-03-04 Treatment of central nervous systemdamage
IL163884A IL163884A (en) 2002-03-04 2004-09-02 Preparation of medicaments to promote neuronal plasticity
IL223875A IL223875A (en) 2002-03-04 2012-12-25 Use of chondroitinase in the preparation of a drug for use in a method of promoting neural flexibility

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL163884A IL163884A (en) 2002-03-04 2004-09-02 Preparation of medicaments to promote neuronal plasticity
IL223875A IL223875A (en) 2002-03-04 2012-12-25 Use of chondroitinase in the preparation of a drug for use in a method of promoting neural flexibility

Country Status (16)

Country Link
US (1) US20050118157A1 (xx)
EP (2) EP1480674B1 (xx)
JP (2) JP5112607B2 (xx)
AT (1) ATE490786T1 (xx)
AU (2) AU2003208466B2 (xx)
CA (1) CA2478645C (xx)
DE (1) DE60335244D1 (xx)
DK (1) DK1480674T3 (xx)
ES (1) ES2357227T3 (xx)
GB (1) GB0205022D0 (xx)
HK (1) HK1073430A1 (xx)
IL (3) IL163884A0 (xx)
MX (1) MXPA04008598A (xx)
PT (1) PT1480674E (xx)
SI (1) SI1480674T1 (xx)
WO (1) WO2003074080A1 (xx)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1274726B1 (en) * 2000-04-13 2009-12-23 Thomas N. Wight Therapeutic compounds and methods for modulating v3, a versican isoform
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
EP1575548B1 (en) * 2002-05-04 2011-03-09 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
DE60334220D1 (de) 2002-06-03 2010-10-28 Massachusetts Inst Technology Rationell konstruierte, von chondroitinase b abgeleitete lyasen
ATE508197T1 (de) * 2002-08-15 2011-05-15 Acorda Therapeutics Inc Chimärisches protein
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
CA2522364C (en) 2003-04-18 2014-12-09 Biogen Idec Ma Inc. Polymer-conjugated glycosylated neublastin
US7959914B2 (en) * 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
AU2004241088B2 (en) * 2003-05-16 2010-08-05 Acorda Therapeutics, Inc. Compositions and methods for the treatment of CNS injuries
EP1646353A4 (en) * 2003-05-16 2008-06-04 Acorda Therapeutics Inc FUSION PROTEINS FOR THE TREATMENT OF THE CENTRAL NERVOUS SYSTEM
ES2616749T3 (es) 2003-05-16 2017-06-14 Acorda Therapeutics, Inc. Mutantes degradantes del proteoglucano para el tratamiento del SNC
EP1737954A2 (en) * 2004-03-10 2007-01-03 The Massachusetts Institute Of Technology Recombinant chondroitinase abc i and uses thereof
WO2005112986A2 (en) * 2004-05-18 2005-12-01 Acorda Therapeutics, Inc. Purifying chondroitinase and stable formulations thereof
CA2577690C (en) 2004-08-19 2013-08-06 Biogen Idec Ma Inc. Refolding transforming growth factor beta family proteins
SI1786454T1 (sl) * 2004-08-19 2010-10-29 Biogen Idec Inc Variante neoblastina
CA2609701A1 (en) * 2005-05-25 2006-11-30 The Johns Hopkins University Compositions and methods for enhancing axon regeneration
JP5189985B2 (ja) 2005-09-26 2013-04-24 アコーダ セラピューティクス、インク． コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法
TWI501774B (zh) * 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US20100056440A1 (en) * 2006-03-01 2010-03-04 Biogen Idec Ma Inc. Compositions and methods for administering gdnf ligand family proteins
JP4147264B2 (ja) * 2006-09-08 2008-09-10 株式会社ステリック再生医科学研究所 神経線維性変性抑制剤
JP5391069B2 (ja) 2006-10-10 2014-01-15 アコーダ セラピューティクス、インク． コンドロイチナーゼａｂｃｉ変異体を使用する組成物及び方法
CA2685686A1 (en) * 2007-05-01 2008-11-13 Biogen Idec Ma Inc. Neublastin polypeptides for use increasing vascularization in a tissue
WO2008149428A1 (ja) * 2007-06-05 2008-12-11 Glycoscience Laboratories, Inc. 自己免疫疾患、炎症及び神経疾患の治療剤及び予防剤
WO2009020964A2 (en) * 2007-08-08 2009-02-12 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
EP2217249A4 (en) * 2007-11-06 2011-10-12 Benaroya Res Inst INHIBITION OF VERSICANE BY ARNS AND OTHER MOLECULES
GB0723825D0 (en) * 2007-12-05 2008-01-23 Ucl Business Plc Composition
JP5636536B2 (ja) * 2008-04-14 2014-12-10 国立大学法人名古屋大学 神経因性疼痛の改善剤
EP2153844A1 (en) * 2008-08-14 2010-02-17 HAUBECK, Hans-Dieter Human hyaluronidases for axonal regrowth
WO2010100247A1 (en) 2009-03-06 2010-09-10 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Novel therapy for anxiety
US20110124706A1 (en) * 2009-11-25 2011-05-26 Zhigang He SOCS3 Inhibition Promotes CNS Neuron Regeneration
JP5885136B2 (ja) * 2011-01-31 2016-03-15 学校法人 愛知医科大学 高硫酸化コンドロイチン硫酸類の合成方法、高硫酸化コンドロイチン硫酸類、および解析用試薬
WO2012136768A1 (en) 2011-04-08 2012-10-11 Hans-Dieter Haubeck Use of mutants of human hyaluronidase ph-20 with increased chondroitinase activity for axonal regrowth
US9511036B2 (en) 2011-11-01 2016-12-06 Children's Medical Center Corporation Co-activation of mTOR and STAT3 pathways to promote neuronal survival and regeneration
EP2900256A1 (en) * 2012-09-25 2015-08-05 The United States of America, as represented by the Secretary, Department of Health and Human Services Treatment of central nervous system (cns) injury
WO2014065669A1 (en) * 2012-10-26 2014-05-01 Stichting Vu-Vumc Methods of treatment and diagnosis for cognitive decline and memory impairment
CN105579578A (zh) * 2013-08-12 2016-05-11 贝纳罗亚研究院·弗吉尼亚梅森 用于免疫调节的4-甲基伞形酮治疗
WO2018029685A1 (en) * 2016-08-11 2018-02-15 Technion Research & Development Foundation Limited Compositions and methods for treating a fear memory

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
CA2071898A1 (en) * 1989-10-27 1991-04-28 Diane M. Snow Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans
JPH06502840A (ja) * 1989-10-27 1994-03-31 ケース ウェスタン リザーブ ユニバーシティ ケラタン硫酸、コンドロイチン硫酸、デルマタン硫酸及び他のグリカンによる細胞成長の阻害
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5496718A (en) 1992-06-26 1996-03-05 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Chondroitinase ABC isolated from proteus vulgaris ATCC 6896
US5773277A (en) 1992-06-26 1998-06-30 Seikagaku Kogyo Kabushiki Kaisha Crystalline chondroitinase isolated from Proteus vulgaris ATCC 6896
US5498536A (en) 1994-04-22 1996-03-12 American Cyanamid Company Chondroitinase II from Proteus vulgaris
JPH10500843A (ja) 1994-04-22 1998-01-27 アメリカン・サイアナミド・カンパニー コンドロイチナーゼｉおよびｉｉ、その製造法および用途
US6093563A (en) 1994-07-08 2000-07-25 Ibex Technologies R And D, Inc. Chondroitin lyase enzymes
US5997863A (en) 1994-07-08 1999-12-07 Ibex Technologies R And D, Inc. Attenuation of wound healing processes
JPH09194502A (ja) * 1995-11-13 1997-07-29 Seikagaku Kogyo Co Ltd 新規コンドロイチン硫酸プロテオグリカン、そのコア蛋白質、それをコードするｄｎａおよびそれに対する抗体
EP0875253B1 (en) * 1997-05-02 2005-04-06 Seikagaku Corporation Chondroitinase compositions
AU772479B2 (en) * 1998-10-06 2004-04-29 Stryker Corporation Repair of larynx, trachea, and other fibrocartilaginous tissues
MXPA04001334A (es) * 2001-08-13 2004-05-05 Univ Florida Materiales y metodos para promover la reparacion de tejido nervioso.
WO2004060146A2 (en) * 2002-12-30 2004-07-22 Purdue Research Foundation Method of treatment for central nervous system injury

Also Published As

Publication number Publication date
GB0205022D0 (en) 2002-04-17
EP1480674B1 (en) 2010-12-08
CA2478645A1 (en) 2003-09-12
HK1073430A1 (en) 2005-10-07
AU2003208466A1 (en) 2003-09-16
PT1480674E (pt) 2011-03-15
AU2003208466B2 (en) 2008-10-02
AU2009200025B2 (en) 2010-11-18
IL223875A (en) 2017-02-28
JP5112607B2 (ja) 2013-01-09
AU2009200025A1 (en) 2009-02-05
JP2005526740A (ja) 2005-09-08
EP2277531A1 (en) 2011-01-26
EP1480674A1 (en) 2004-12-01
CA2478645C (en) 2011-11-29
ATE490786T1 (de) 2010-12-15
ES2357227T3 (es) 2011-04-20
WO2003074080A1 (en) 2003-09-12
SI1480674T1 (sl) 2011-04-29
DE60335244D1 (de) 2011-01-20
MXPA04008598A (es) 2005-09-08
DK1480674T3 (da) 2011-03-28
IL163884A (en) 2013-01-31
US20050118157A1 (en) 2005-06-02
JP2010132682A (ja) 2010-06-17

Similar Documents

Publication Publication Date Title
IL163884A0 (en) Treatment of central nervous systemdamage
HUS1300069I1 (hu) Dextrometorfánt és kinidint tartalmazó gyógyászati készítmények neurológiai rendellenességek kezelésére
IL188249A0 (en) Cephalosporin related compounds for use in therapy
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
ZA200204416B (en) Carbon dioxide enhancement of inhalation therapy.
WO2005004814A3 (en) Sirt1 and genetic disorders
EP0958824A3 (en) Olanzapine (zyprexa) in combination with fluoxetine (prozac), lithium or anticonvulsant for therapy of refractory depression
HUP0303900A2 (hu) Az arteminnek, a GDNF ligandum család egy tagjának új alkalmazása
ATE237680T1 (de) Transplantation von hämatopoietischen zellen
MXPA05012305A (es) Composiciones y metodos para el tratamiento de lesiones del snc.
MXPA05009986A (es) Tratamiento de la enfermedad de alzheimer.
AU2003304173A1 (en) Compositions and methods for promoting neuronal outgrowth
AUPS255402A0 (en) Agents and methods for the treatment of disorders associated with oxidative stress
ITVR20020071A1 (it) Procedimento ed attrezzatura per l'appassimento dell'uva.
UA33498A (uk) Спосіб лікування терапевтично резистентних форм шизофренії
AU2003287513A1 (en) INHIBITORS OF Beta-SECRETASE, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE OR MILD COGNITIVE IMPAIRMENT
EP1210103A4 (en) INDUCED REGENERATION AND REPAIR OF DAMAGED NEURONES AND THE AXONMYELIN OF NERVES
SI1534286T1 (sl) Postopki za zdravljenje ali prepreŽŤevanje avtoimunskih bolezni z 2,4-pirimidindiaminskimi spojinami
WO2005013895A3 (en) Compositions and methods for the treatment of schizophrenia and addictive disorders
MX349462B (es) Composiciones y metodos para el tratamiento de lesiones del snc.
UA32146A (uk) Спосіб оцінки ефективності лікування пародонтита
UA32235A (uk) Спосіб моделювання закритої травми нирки в експерименті